Cold atmospheric plasma to improve cannulation-site wound healing after extracorporeal life support
Investigating the Impact of Cold Atmospheric Plasma Treatment on Wound Healing at Cannulation Sites in Patients Following Extracorporeal Life Support
NA · National Taiwan University Hospital · NCT07501897
This trial will test whether adding cold atmospheric plasma (CAP) to standard wound care helps adults on extracorporeal life support heal cannulation-site wounds faster and with fewer infections.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 65 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | National Taiwan University Hospital (other) |
| Locations | 1 site (Taipei) |
| Trial ID | NCT07501897 on ClinicalTrials.gov |
What this trial studies
This is a randomized, controlled trial enrolling adults on extracorporeal life support (ECLS) who have cannulation-site wounds. Participants are randomized 1:1 to receive standard wound care alone or standard care plus topical cold atmospheric plasma (CAP) applied at predefined intervals using a medical device. Outcomes include quantitative bacterial burden (fluorescence imaging and cultures), cytokine analysis of wound exudate, clinical wound-healing scores, wound surface measurements, time to epithelialization, need for surgical debridement, infection incidence, and safety monitoring. The study aims to determine whether CAP reduces biofilm and inflammation and accelerates healing in this high-risk population.
Who should consider this trial
Good fit: Adults aged 18 or older who are receiving extracorporeal life support and have a cannulation-site wound requiring wound care, without severe local dermatologic disease or prohibitive coagulopathy and with expected survival beyond 48 hours, are ideal candidates.
Not a fit: Patients with severe pre-existing skin conditions at the cannulation site, significant coagulopathy that precludes local intervention, those receiving other experimental wound therapies, or those with life expectancy under 48 hours may not benefit or be eligible.
Why it matters
Potential benefit: If successful, CAP could speed wound closure, reduce infection and biofilm burden, and lower the need for additional procedures in ECLS cannulation-site wounds.
How similar studies have performed: Smaller clinical and preclinical studies have shown CAP can reduce bacteria and promote healing in chronic and acute wounds, but its specific use for ECLS cannulation sites is relatively novel and not yet widely studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Receiving extracorporeal life support (ECLS) * Presence of cannulation site wound requiring wound care Exclusion Criteria: * Pre-existing severe dermatological conditions at the cannulation site * Severe coagulopathy precluding local intervention * Concurrent receipt of other experimental wound treatments * Life expectancy \< 48 hours
Where this trial is running
Taipei
- National Taiwan University Hospital — Taipei, Taiwan (RECRUITING)
Study contacts
- Study coordinator: CHIH-YANG CHAN
- Email: chanchihyang@gmail.com
- Phone: +886-975810806
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: ExtraCorporeal Life Support, Wound Infection, Surgical Site Infection, Delayed Wound Healing, Biofilm-Associated Infection, Extracorporeal Life Support, cold atmospheric plasma